Revelation Biosciences (REVB) Retained Earnings (2020 - 2026)
Revelation Biosciences (REVB) posted quarterly Retained Earnings of -$49.4 million for Q4 2025, down 209.3% year-over-year from $45.2 million in Q4 2024, and down 5.37% quarter-over-quarter from -$46.9 million in Q3 2025.
Revelation Biosciences (REVB) Retained Earnings (2020 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Retained Earnings for 6 consecutive years, with -$49.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings fell 209.3% year-over-year to -$49.4 million; the TTM figure through Dec 2025 stood at -$49.4 million (down 209.3% YoY), while the FY2025 annual figure was -$49.4 million, down 209.3% from the prior year.
- Retained Earnings slipped to -$49.4 million in Q4 2025 per REVB's latest filing, from -$46.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $48.8 million in Q2 2025 and bottomed at -$49.4 million in Q4 2025.
- Historically, Retained Earnings has averaged -$1.4 million across 5 years, with a median of -$6.2 million in 2021.
- Annual changes were most pronounced in 2021 — Retained Earnings plunged 29011.04% — and 2022, when it jumped 498.87%.
- Revelation Biosciences' Retained Earnings stood at $14.4 million in 2021, then jumped by 83.1% to $26.4 million in 2022, then plunged by 196.47% to -$25.5 million in 2023, then jumped by 277.54% to $45.2 million in 2024, then sank by 209.3% to -$49.4 million in 2025.
- Business Quant data shows REVB's Retained Earnings at -$49.4 million in Q4 2025, -$46.9 million in Q3 2025, and $48.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 4.38 Bn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | 65.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.81 Mn |
| Dec 31, 2025 | -49.42 Mn |
| Sep 30, 2025 | -46.90 Mn |
| Jun 30, 2025 | 48.83 Mn |
| Mar 31, 2025 | -42.60 Mn |
| Dec 31, 2024 | 45.21 Mn |
| Sep 30, 2024 | 41.45 Mn |
| Jun 30, 2024 | 37.68 Mn |
| Mar 31, 2024 | -28.15 Mn |
| Dec 31, 2023 | -25.47 Mn |
| Sep 30, 2023 | -23.30 Mn |
| Jun 30, 2023 | -20.60 Mn |
| Mar 31, 2023 | 29.20 Mn |
| Dec 31, 2022 | 26.40 Mn |
| Sep 30, 2022 | 26.34 Mn |
| Jun 30, 2022 | -23.00 Mn |
| Mar 31, 2022 | -21.13 Mn |
| Dec 31, 2021 | 14.42 Mn |
| Sep 30, 2021 | -6.60 Mn |
| Jun 30, 2021 | -5.85 Mn |